Oxford’s research team has unparalleled expertise and an unmatched history of innovation, authoring 9 United States patents and 17 International patents related to diet-induced inflammation technology. No other company comes close. In collaboration with Sony Biotechnologies, Oxford’s latest innovation is the MRTIII® instrument. MRTIII® is the world’s most advanced and reliable instrument for measuring the subtle volumetric changes that occur in hidden inflammatory reactions to foods and food-chemicals.
MRTIII provides unmatched reliability and precision because it is the only instrument in the industry that combines advanced flow cytometry technology with the patented impedance-based “Ribbon Method.” MRTIII®, along with Oxford’s patented method, is the only instrument capable of measuring the effects of antigen challenge on individual white cell populations simultaneously (lymphocytes, eosinophils, monocytes, neutrophils). And because MRTIII® is able to identify more relevant inflammatory reactions than any other test or method, therapeutic outcomes are maximized with its use.
Additional applications for MRTIII® in the fields of pharmaceutical research, cytokine quantification, and quality control applications in particle counting and sizing where extreme precision is required, are projected for the near future.
Mediator Release Testing:
Because of the development of MRTIII, Oxford is able to provide healthcare practitioners the patented Mediator Release Test (MRT). Mediator release is the key pathological event associated with food-induced inflammation. MRT provides clinically significant information no other blood test or method can provide. MRT is a functional assay that quantifies and measures the subtle volumetric changes that occur in white blood cells after positive antigen challenges, and that correlate with release of cytokines, leukotrienes, prostaglandins and other pro-inflammatory mediators.
Therapeutic Protocols: The LEAP Anti-Inflammatory Eating Plan
Although the information MRT® provides is critical in identifying hidden inflammatory foods and chemicals, it is the practical implementation of the test results that produces the desired health benefits, not the test itself. For this reason, Oxford created the LEAP Program (Lifestyle Eating And Performance), a unique, innovative and extremely effective patient-specific anti-inflammatory eating plan.
LEAP is much more than just a computer generated rotation diet based on the results of a blood test. LEAP was developed and refined in a clinical setting over several years on thousands of diet-induced inflammation patients (Oxford Nutritional Centers). This clinical development created an approach that routinely and predictably achieved the most complete outcomes in the shortest time, and was significantly easier to follow than rotation diets or other available diet-based approaches. Fast, reliable, and complete relief are the common goals of every patient and practitioner dealing with the unwanted effects of diet-induced inflammation. This is what LEAP provides.
The primary reason that diet-induced inflammation is one of the most neglected areas of treatment in conventional medicine is because they’re one of the most under-addressed areas of practitioner training. Most of conventional medicine doesn’t understand the clinical signs of non-allergic diet-induced inflammation. Because of this, and with the recognition that a properly trained dietetic professional is the ideal practitioner to manage the needs of food-related illness, in 2006, Oxford created the Certified LEAP Therapist training course (CLT). The CLT course provides an excellent understanding of the different types of adverse food reactions, with an emphasis on the important role that diet-induced inflammation play in IBS, migraine, and fibromyalgia.